Safety & Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03013647` - Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization	N/A
Completed	`NCT02674048` - Metvix Daylight PDT in Actinic Keratosis
Completed	`NCT02421471` - PMS to Evaluate the Safety and Efficacy of Picato® Gel
Completed	`NCT02239679` - Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy	Phase 2
Completed	`NCT01686152` - Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis	Phase 3
Completed	`NCT01444989` - Development and Validation of a Quality of Life Instrument for Actinic Keratosis	N/A
Terminated	`NCT01525329` - Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease	Phase 3
Completed	`NCT01449513` - PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy	Phase 1
Terminated	`NCT01203878` - Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy	Phase 4
Completed	`NCT00989313` - A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study	Phase 3
Completed	`NCT00306800` - Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp	Phase 3
Completed	`NCT00375739` - Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses	Phase 2
Completed	`NCT03285490` - A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)	Phase 3
Completed	`NCT03319251` - Biomarker Database Registry for Photodynamic Therapy
Completed	`NCT02866695` - Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients	Phase 4
Completed	`NCT02952898` - Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses	Phase 3
Completed	`NCT02984072` - Menthol for PDT Pain Relief	Phase 4
Recruiting	`NCT03684772` - Topical Ionic Contra-Viral Therapy in Actinic Keratosis	Phase 2
Completed	`NCT02938715` - Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil	N/A
Completed	`NCT02902822` - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo	N/A

NCT number	NCT02120456
Study type	Interventional
Source	LEO Pharma
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	May 2014
Completion date	May 2015

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms